THE APPROPRIATE use of heparin continues to be one of the most contentious and controversial issues in the fields of neurology and medicine. The introduction of fractionated low-molecular-weight heparin and heparinoids has further complicated the issue for clinicians. Although these newer compounds have theoretical and practical advantages, most clinicians have had little experience with them, and few data are available to guide rational choice between different pharmaceutical products. Clinicians ask, "Which product should be given to which patients, by what route, with or without an initial bolus, at what dose, monitored how, and when should the treatment be started?"
Caplan LR. When Should Heparin Be Given to Patients With Atrial Fibrillation–Related Embolic Brain Infarcts?. Arch Neurol. 1999;56(9):1059-1060. doi:10.1001/archneur.56.9.1059